Insmed Inc (INSM) 15.32 $INSM
Insmed Announces Data Presentations for ARIKAYCE in Two Orphan Lung Diseases at the American Thoracic Society Meeting
Marketwire - Tue May 13, 7:15AM CDT
Insmed Incorporated (NASDAQ: INSM) announces that multiple poster presentations reporting data on ARIKAYCE(TM), or liposomal amakacin for inhalation, for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients and for the treatment of patients with treatment-resistant nontuberculous mycobacterial (NTM) lung infections will be presented at the American Thoracic Society Annual Meeting 2014, taking place May 16-21 in San Diego, California.
Insmed to Participate in the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Mon May 12, 7:15AM CDT
Insmed Incorporated (NASDAQ: INSM) announces that Company management will be participating at the Bank of America Merrill Lynch 2014 Health Care Conference taking place from May 13-15, 2014 at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Insmed Reports First Quarter 2014 Financial Results
Marketwire - Thu May 08, 6:50AM CDT
Insmed Incorporated (NASDAQ: INSM) today reported financial results for the three months ended March 31, 2014.
15.8% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Wed May 07, 9:27AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on March 26th, 2014 at $16.47. In approximately 1 month, Insmed has returned 15.83% as of today's recent price of $13.86.
Therapure Biomanufacturing Awarded Manufacturing Contract for Insmed's ARIKAYCE™
PRWeb - Tue Apr 29, 3:54AM CDT
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation.
Therapure Biomanufacturing Awarded Manufacturing Contract for Insmed's ARIKAYCE(TM)
GlobeNewswire - Tue Apr 29, 3:03AM CDT
via PRWEB - Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Apr 24, 8:30AM CDT
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
Equities Updates on Top Gainers -- Research on Micron Technology, SINA, Mobile Telesystems, and Insmed
PR Newswire - Mon Apr 21, 9:00AM CDT
The US markets saw a mixed sentiment on Thursday, April 17, 2014, with the NASDAQ Composite closing at 4,095.52, up 0.23%, the Dow Jones Industrial Average ending the session at 16,408.54, down 0.10%, and the S&P 500 edging 0.14% higher to finish the trading session at 1,864.85. The session saw a positive impact from Energy, Industrials and Telecommunication Services sectors along with a drag from Information Technology, and Utilities sectors. A number of stocks saw large movements, including Micron Technology Inc. (NASDAQ: MU), SINA Corp. (NASDAQ: SINA), Mobile Telesystems OJSC (NYSE: MBT) and Insmed Inc. (NASDAQ: INSM). Free technical research on MU, SINA, MBT and INSM can be downloaded upon signing up at:
Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
Marketwire - Mon Apr 07, 3:45PM CDT
Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13th Annual Needham & Co. Healthcare Conference taking place from April 8 - 9, 2014 at the Westin Grand Central Hotel in New York City.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 31, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Insmed Announces Data Presentations for ARIKAYCE in Two Orphan Lung Diseases at the American Thoracic Society Meeting
Marketwire - Tue May 13, 7:15AM CDT
Insmed Incorporated (NASDAQ: INSM) announces that multiple poster presentations reporting data on ARIKAYCE(TM), or liposomal amakacin for inhalation, for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients and for the treatment of patients with treatment-resistant nontuberculous mycobacterial (NTM) lung infections will be presented at the American Thoracic Society Annual Meeting 2014, taking place May 16-21 in San Diego, California.
Insmed to Participate in the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Mon May 12, 7:15AM CDT
Insmed Incorporated (NASDAQ: INSM) announces that Company management will be participating at the Bank of America Merrill Lynch 2014 Health Care Conference taking place from May 13-15, 2014 at the Encore at the Wynn Hotel in Las Vegas, Nevada.
Insmed Reports First Quarter 2014 Financial Results
Marketwire - Thu May 08, 6:50AM CDT
Insmed Incorporated (NASDAQ: INSM) today reported financial results for the three months ended March 31, 2014.
15.8% Return Seen to Date on SmarTrend Insmed Call (INSM)
Comtex SmarTrend(R) - Wed May 07, 9:27AM CDT
SmarTrend identified a Downtrend for Insmed (NASDAQ:INSM) on March 26th, 2014 at $16.47. In approximately 1 month, Insmed has returned 15.83% as of today's recent price of $13.86.
Therapure Biomanufacturing Awarded Manufacturing Contract for Insmed's ARIKAYCE™
PRWeb - Tue Apr 29, 3:54AM CDT
Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation.
Therapure Biomanufacturing Awarded Manufacturing Contract for Insmed's ARIKAYCE(TM)
GlobeNewswire - Tue Apr 29, 3:03AM CDT
via PRWEB - Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with Insmed Incorporated for the manufacture of ARIKAYCE, liposomal amikacin for inhalation.
3 Stocks Spiking on Unusual Volume
at The Street - Thu Apr 24, 8:30AM CDT
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.
Equities Updates on Top Gainers -- Research on Micron Technology, SINA, Mobile Telesystems, and Insmed
PR Newswire - Mon Apr 21, 9:00AM CDT
The US markets saw a mixed sentiment on Thursday, April 17, 2014, with the NASDAQ Composite closing at 4,095.52, up 0.23%, the Dow Jones Industrial Average ending the session at 16,408.54, down 0.10%, and the S&P 500 edging 0.14% higher to finish the trading session at 1,864.85. The session saw a positive impact from Energy, Industrials and Telecommunication Services sectors along with a drag from Information Technology, and Utilities sectors. A number of stocks saw large movements, including Micron Technology Inc. (NASDAQ: MU), SINA Corp. (NASDAQ: SINA), Mobile Telesystems OJSC (NYSE: MBT) and Insmed Inc. (NASDAQ: INSM). Free technical research on MU, SINA, MBT and INSM can be downloaded upon signing up at:
Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference
Marketwire - Mon Apr 07, 3:45PM CDT
Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13th Annual Needham & Co. Healthcare Conference taking place from April 8 - 9, 2014 at the Westin Grand Central Hotel in New York City.
3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.
Nasdaq stocks posting largest percentage increases
AP - Mon Mar 31, 12:47PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 29, 2:15PM CDT
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
